Edition:
United Kingdom

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

11.28USD
25 Apr 2019
Change (% chg)

$-0.12 (-1.05%)
Prev Close
$11.40
Open
$11.41
Day's High
$11.41
Day's Low
$11.28
Volume
6,023
Avg. Vol
48,319
52-wk High
$18.00
52-wk Low
$8.20

Latest Key Developments (Source: Significant Developments)

Eiger Biopharmaceuticals Q4 Loss Per Share $0.92
Thursday, 14 Mar 2019 

Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.92.AS OF DECEMBER 31, 2018, COMPANY HAD 19.2 MILLION OF COMMON SHARES OUTSTANDING..  Full Article

Eiger's Lonafarnib Gets Breakthrough Therapy Label In Progeria And Progeroid Laminopathies
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER ANNOUNCES BREAKTHROUGH THERAPY DESIGNATION GRANTED BY FDA FOR LONAFARNIB IN PROGERIA AND PROGEROID LAMINOPATHIES.EIGER BIOPHARMACEUTICALS INC - NDA FILING PLANNED IN 2019.  Full Article

Eiger Announces Prime Designation Granted By European Medicines Agency For Lonafarnib For Treatment Of Hepatitis Delta Virus Infection
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER ANNOUNCES PRIME DESIGNATION GRANTED BY EUROPEAN MEDICINES AGENCY FOR LONAFARNIB FOR TREATMENT OF HEPATITIS DELTA VIRUS INFECTION.EIGER BIOPHARMACEUTICALS INC - PHASE 3 HDV "D-LIVR" INTERNATIONAL STUDY INITIATING.  Full Article

Eiger Biopharmaceuticals announces the appointment of Sri Ryali as chief financial officer
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF SRI RYALI AS CHIEF FINANCIAL OFFICER.EIGER BIOPHARMACEUTICALS INC - JAMES WELCH, EIGER'S PREVIOUS CHIEF FINANCIAL OFFICER, HAS LEFT COMPANY.  Full Article

Eiger Bio Reports Q3 Loss Per Share $1.20
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.20.Q3 EARNINGS PER SHARE VIEW $-0.74 -- THOMSON REUTERS I/B/E/S.HDV PHASE 3 D-LIVR STUDY START IN 2018 AND PROGERIA NDA PLANNED IN 2019.EIGER BIOPHARMACEUTICALS - "COMPANY IS NOW PREPARING NEW DRUG APPLICATION IN PROGERIA, ENROLLING FIRST-EVER PHASE 3 STUDY IN HEPATITIS DELTA VIRUS INFECTION"."TARGETING REGULATORY GUIDANCE IN POST-BARIATRIC HYPOGLYCEMIA (PBH) IN 2019".  Full Article

Eiger Biopharmaceuticals Inc Qtrly Loss Per Share $0.82
Friday, 10 Aug 2018 

Aug 10 (Reuters) - Eiger BioPharmaceuticals Inc ::QTRLY LOSS PER SHARE $0.82.Q2 EARNINGS PER SHARE VIEW $-0.82 -- THOMSON REUTERS I/B/E/S.  Full Article

Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common Stock
Wednesday, 23 May 2018 

May 23 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.EIGER BIOPHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK.EIGER BIOPHARMACEUTICALS - PLANS TO USE NET PROCEEDS TO FUND PLANNED PHASE 3 CLINICAL TRIAL OF LONAFARNIB IN HEPATITIS DELTA VIRUS INFECTION, OTHERS.  Full Article

Eiger Biopharmaceuticals Reports First Quarter 2018 Financial Results
Friday, 11 May 2018 

Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.84.Q1 EARNINGS PER SHARE VIEW $-1.04 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, EIGER HAD CASH, CASH EQUIVALENTS AND SHORT-TERM DEBT SECURITIES OF $33.2 MILLION.  Full Article

Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018​
Wednesday, 21 Mar 2018 

March 21 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM.EIGER BIOPHARMACEUTICALS INC - ‍PHASE 3 D-LIVR TRIAL PLANNED TO INITIATE IN SECOND HALF 2018​.EIGER BIOPHARMACEUTICALS INC - PHASE 3 D-LIVR TRIAL PLANNED TO INITIATE IN SECOND HALF 2018.EIGER BIOPHARMACEUTICALS INC - EXPECT TO SHARE ADDITIONAL INFORMATION ON PLANNED REGISTRATION PROGRAM IN 2Q 2018.EIGER BIOPHARMACEUTICALS - ‍LIFT ENROLLMENT PLANNED FOR 2Q 2018​.  Full Article

Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - END OF PHASE 2 MEETING SCHEDULED FOR HDV IN FEBRUARY 2018.EIGER BIOPHARMACEUTICALS INC - NO SAFETY SIGNALS ATTRIBUTED TO UBENIMEX WERE IDENTIFIED IN PRELIMINARY ANALYSIS.EIGER BIOPHARMACEUTICALS - FURTHER ANALYSIS OF DATA, INCLUDING BIOMARKERS IS ONGOING, ALTHOUGH CO TO DISCONTINUE DEVELOPMENT OF UBENIMEX IN PAH.EIGER BIOPHARMACEUTICALS INC - WILL CONTINUE TO DEVELOP UBENIMEX FOR LYMPHEDEMA BASED ON ITS DISTINCT MECHANISM OF ACTION IMPACTING LYMPHANGIOGENESIS.EIGER BIOPHARMACEUTICALS INC - EIGER IS DEVELOPING UBENIMEX FOR LYMPHEDEMA IN ULTRA STUDY.  Full Article